Therefore, our findings suggest that PKA activators or phosphodiesterase (PDE) inhibitors could serve as potential therapeutic agents to preserve dopaminergic neuron lifespan in the substantia nigra of PD patients and slow disease progression. The gene discussed is ALDH7A1; the disease is Parkinson disease.